Mushroom Compounds and Tight Junction Protein Expression

Mushrooms & Gut Barrier

3 proteins

Tight junction integrity depends on three key proteins: ZO-1, occludin, and claudin. Multiple mushroom polysaccharides have been shown to prevent their degradation or restore their expression after gut injury, including a 2025 study using actual human colonic tissue.

Kerezoudi et al., Nutrients, 2025

Human tissue

2025 King Oyster study tested tight junction protection in human colonic cells

Primate data

Hericium mycelium alleviated gut injury in a cynomolgus monkey model

2 routes

indirect via butyrate and direct via NF-κB inhibition

Kerezoudi et al., Nutrients, 2025

View as image ↗

The gut lining is held together by molecular fasteners called tight junction proteins. When these proteins degrade, gaps form between intestinal cells and undigested particles, bacterial fragments, and toxins can pass directly into the bloodstream. A small but growing body of research shows that specific mushroom polysaccharides can prevent tight junction protein degradation, or restore their expression after gut injury, through mechanisms that include both direct anti-inflammatory effects and indirect action through the gut microbiome. This article focuses on the biology: which proteins are involved, which studies measured them, and what the evidence actually shows for mushroom tight junction proteins.

For the broader context of how mushroom polysaccharides feed the gut microbiome and why that matters for gut barrier health, Mushrooms as Prebiotics: How They Feed Your Gut Bacteria provides the foundation. This article goes deeper on the tight junction mechanism specifically.

What Tight Junction Proteins Are and Why They Break Down

Tight junction proteins are the molecular glue that holds intestinal cells side by side. The gut lining is a single layer of epithelial cells. In a healthy gut, these cells are sealed together so tightly that very little can pass between them; only properly processed nutrients move through the cells themselves, not between them.

Three proteins do most of the structural work. ZO-1 (zonula occludens-1) is the scaffold protein: it sits just inside the cell membrane and anchors the junction to the cell's internal skeleton. Occludin and claudin are the transmembrane proteins that extend through the cell membrane and physically lock onto the occludin and claudin molecules in the neighboring cell, forming a tight molecular seal.

When these proteins are degraded or their expression is reduced, the tight junction loosens. Gaps form between intestinal cells. This allows bacteria, bacterial toxins (particularly LPS, a fragment of gram-negative bacterial cell walls), and undigested proteins to pass into the lamina propria and eventually the bloodstream. This state has been called intestinal hyperpermeability or, colloquially, leaky gut.

What causes tight junction breakdown? Chronic inflammation is the primary driver, particularly the signaling cascade involving NF-κB (the master inflammation switch) and related pathways. When NF-κB is chronically overactivated, as it is in IBD, it directly suppresses the expression of tight junction proteins. Bile acids (especially deoxycholic acid) have also been shown to disrupt tight junctions, which is relevant because bile acid concentrations in the gut vary substantially based on diet and microbiome composition. Antibiotics and chemotherapy drugs are two other common causes of tight junction disruption through their effects on the gut microbiome and epithelial cells directly.

Beta-glucans are polysaccharides found in mushroom cell walls. In the context of tight junction biology, their mechanism falls into two routes, and both are relevant to understanding why multiple mushroom species consistently show gut barrier effects in animal studies. For a deeper look at how mushroom beta-glucans interact with the gut immune system more broadly, Mushroom Beta-Glucans and Gut Inflammation: IBD Research covers that territory in full.

The 2025 King Oyster Study: Tight Junction Protection in Human Colonic Tissue

The most clinically relevant study in this field was published in 2025 by Kerezoudi and colleagues in Nutrients.

The experimental design was unusual and notably rigorous for this research area. The researchers first fermented King Oyster mushroom (Pleurotus eryngii) with actual human fecal microbiota, essentially letting the mushroom be pre-processed by the same bacteria present in a real gut. The fermented product was then applied to healthy human colonic tissue, which was simultaneously challenged with deoxycholic acid, a bile acid that is a well-established disruptor of tight junction integrity.^[1]

The result: the King Oyster ferment preserved tight junction integrity against the bile acid challenge. Immune signaling pathways were modulated in the treated tissue in ways consistent with reduced inflammatory activity.

Two aspects of this study set it apart from most mushroom gut research. First, it used human colonic tissue, not mouse intestine. The tight junction architecture and immune signaling of human gut cells is meaningfully different from rodent gut cells. Second, it challenged the tissue with a physiologically relevant stressor (deoxycholic acid), not an artificial chemical model. Bile acid exposure is a real condition that occurs in the human gut, particularly at higher concentrations that can result from high-fat diets or certain microbiome profiles.

No consumer-facing mushroom gut health article had covered this study before this piece was written.

Lion's Mane and Tight Junctions: The Primate Study and the Chemotherapy Model

Hericium erinaceus has the most accumulated gut barrier evidence of any mushroom species, and two studies stand out for specific reasons.

Ren and colleagues published a 2023 study testing Hericium erinaceus mycelium-derived polysaccharide in cynomolgus monkeys, a non-human primate species whose gut anatomy and microbiome composition are considerably closer to humans than mice.^[2] The monkeys had ulcerative colitis induced, and the Hericium treatment alleviated disease and modulated gut microbiota toward a healthier composition. The significance of a primate model is straightforward: results that hold in monkeys are more likely to translate to humans than results that hold only in rodents.

Tian and colleagues published a 2023 study that addresses a different and clinically practical question: can Hericium polysaccharides protect the gut barrier when it is disrupted by chemotherapy?^[3] The researchers used cyclophosphamide, an immunosuppressive chemotherapy drug that is well-known to damage the intestinal mucosa, in a mouse model. Hericium erinaceus polysaccharides restored tight junction protein expression and improved gut mucosal architecture in the treated mice.

This study is particularly relevant because gut barrier disruption from chemotherapy is a real clinical problem. Cyclophosphamide damages intestinal epithelium directly and suppresses immune cell renewal in the gut lining. The finding that a mushroom polysaccharide could restore tight junction proteins after this specific type of injury is a distinct research question from testing in healthy animals or standard colitis models.

How Beta-Glucans Upregulate Tight Junction Proteins Through Two Routes

Understanding why mushroom polysaccharides affect tight junction proteins requires following the chain of events rather than assuming a single direct effect.

Route 1: The prebiotic-to-butyrate pathway. Mushroom beta-glucans act as prebiotics: beneficial gut bacteria, particularly Bifidobacterium, Lactobacillus, and butyrate-producing Ruminococcaceae. These bacteria ferment the polysaccharides and produce butyrate as a byproduct. Butyrate is the primary fuel for colonocytes (colon cells), and it also directly upregulates the expression of occludin and claudin tight junction proteins through gene signaling. When butyrate is abundant, tight junction protein expression is maintained. When butyrate is deficient (as in IBD, after antibiotic treatment, or in certain IBS subtypes), tight junction expression can fall.

Route 2: The direct anti-inflammatory pathway. When NF-κB and related inflammatory pathways (particularly MAPK) are chronically activated, they suppress tight junction gene expression. Multiple mushroom polysaccharides have demonstrated the ability to inhibit NF-κB activation. When this inhibition occurs, the suppression on tight junction gene expression is lifted and protein levels can recover.

These two routes are not mutually exclusive. Studies on Hericium, for example, have shown evidence for both microbiota modulation (supporting butyrate production) and NF-κB pathway inhibition. The combination may explain why multiple species consistently show gut barrier effects despite having different polysaccharide structures.

For a detailed account of how mushroom compounds change the gut microbiome composition through the prebiotic route, How Mushrooms Change Your Gut Microbiome: Research Review covers the microbiota evidence across species.

Poria Cocos: Tight Junction Evidence Across Two Distinct Gut Injury Models

Poria cocos, a traditional Chinese medicinal mushroom also known as Fu Ling, has been tested in two gut injury models that reflect different real-world gut barrier threats.

Xu and colleagues published a 2023 study examining Poria cocos polysaccharide in a mouse model of antibiotic-associated diarrhea.^[4] Antibiotic treatment disrupts the gut microbiome and often damages the intestinal mucosal barrier, leading to diarrhea and increased permeability. In this model, Poria cocos polysaccharide restored intestinal mucosal barrier integrity by normalizing the gut microbiota composition disturbed by antibiotic treatment.

Wan and colleagues published a 2024 study using the DSS-induced colitis model, a standard approach where dextran sulfate sodium directly damages the gut epithelium, closely approximating IBD-type injury.^[5] Poria cocos polysaccharide reduced disease severity by modulating intestinal inflammation and correcting the microbial dysbiosis that DSS treatment produced.

The relevance of testing in two different injury models is practical: antibiotic-associated gut barrier disruption and IBD-type colitis are mechanically different. Antibiotics primarily disrupt the microbiome, which indirectly affects tight junction proteins through reduced butyrate production. DSS directly damages the epithelial layer through oxidative stress and inflammation. Poria cocos polysaccharide showing efficacy in both contexts suggests it is acting through multiple pathways rather than a single narrow mechanism.

The IBS connection deserves a mention here. A 2025 study used a mushroom blend in an ex vivo model of IBS patient microbiomes and found it restored butyrate production, with downstream benefits for barrier integrity, linking the mushroom polysaccharide mechanism directly to a common clinical condition. For readers interested in that specific intersection, Mushrooms for IBS: Can They Help or Hurt? explores the IBS-specific evidence.

What the Evidence Shows, and What It Doesn't

The existing research establishes that mushroom polysaccharides can affect tight junction protein expression through two well-characterized mechanisms. The evidence base includes animal studies (mouse colitis and diarrhea models), a non-human primate study that provides stronger translational value, and a 2025 study in actual human colonic tissue.

What the evidence does not include: a human clinical trial where participants took a mushroom supplement and researchers measured tight junction protein expression or intestinal permeability markers before and after. That study does not exist yet for any mushroom species.

This matters for interpreting the research. The 2025 Kerezoudi study is the closest to human evidence, but it is an ex vivo model: the tissue was removed from humans and tested in a laboratory setting, not in a living person receiving treatment. The primate study used a model animal; monkeys are not humans.

The honest state of the evidence: there is good mechanistic and preclinical support for the idea that mushroom polysaccharides protect and restore tight junction proteins. The specific proteins most commonly affected in these studies include ZO-1, occludin, and claudin-1. No human dose for tight junction support has been established. The most evidence-supported species for this outcome, based on study count and model strength, is Hericium erinaceus, with King Oyster mushroom providing the only human tissue data.

For the practical species-by-species comparison and what the evidence hierarchy looks like from a consumer standpoint, Mushroom Polysaccharides and Tight Junction Protein Expression: Fixing Leaky Gut covers that ground. And for the full range of preclinical models across species, Mushrooms for Intestinal Permeability: Preclinical Evidence maps the data comprehensively.

The Bottom Line

Tight junction proteins ZO-1, occludin, and claudin form the molecular seal between gut cells. When they degrade, intestinal permeability increases. Multiple mushroom polysaccharides have been shown to prevent this degradation or restore these proteins after gut injury, acting through two routes: indirectly via prebiotic-butyrate-mediated upregulation of tight junction genes, and directly via NF-κB pathway inhibition. The strongest evidence comes from Hericium erinaceus (primate model, immunocompromised mouse model) and a 2025 King Oyster study using human colonic tissue. No human clinical trial exists yet; all evidence is animal or tissue-based.

Frequently Asked Questions

What are tight junction proteins in the gut?

Tight junction proteins are structural proteins that seal the gaps between gut epithelial cells, preventing undigested particles and bacteria from passing directly into the bloodstream. The three most studied are ZO-1, which anchors the junction to the cell's internal skeleton; occludin, which spans the cell membrane and locks onto neighboring cells; and claudin, which forms the primary transmembrane seal. When chronic inflammation, antibiotics, or bile acids degrade these proteins, intestinal permeability increases, a condition sometimes called leaky gut. Mushroom polysaccharides have been shown to prevent this degradation and restore protein expression in multiple preclinical models.

Do mushrooms affect ZO-1 or occludin expression?

Yes, in preclinical research. Hericium erinaceus polysaccharides restored tight junction protein expression (including ZO-1 and occludin) in mice whose gut barriers were disrupted by cyclophosphamide chemotherapy treatment (Tian et al., Food and Function, 2023). The 2025 King Oyster study (Kerezoudi et al., Nutrients, 2025) demonstrated preserved tight junction integrity in human colonic tissue challenged with a bile acid. Poria cocos polysaccharide also restored intestinal mucosal barrier integrity in two separate gut injury models. No human clinical trial has measured ZO-1 or occludin changes in response to mushroom supplementation.

Which mushroom compounds protect the gut lining?

Beta-glucan polysaccharides are the primary compounds studied for gut barrier protection. They work through two routes: acting as prebiotics that increase butyrate-producing gut bacteria (butyrate directly upregulates tight junction gene expression), and inhibiting NF-κB signaling (the inflammatory pathway that suppresses tight junction protein expression when overactivated). The species with the most gut barrier evidence are Hericium erinaceus (mouse and primate models plus an immunocompromised mouse study), King Oyster (Pleurotus eryngii, human colonic tissue study, 2025), and Poria cocos (two separate gut injury models). No established clinical dose exists.

How do beta-glucans affect the intestinal barrier?

Beta-glucans affect the intestinal barrier through two mechanisms. First, they act as prebiotics: beneficial gut bacteria ferment beta-glucans and produce butyrate. Butyrate is the primary fuel for colonocytes and directly upregulates the expression of occludin and claudin tight junction proteins at the gene level. Second, beta-glucans and associated mushroom compounds inhibit NF-κB and MAPK inflammatory pathways. These pathways, when chronically activated (as in IBD), suppress tight junction gene expression. By reducing their activation, mushroom polysaccharides allow tight junction protein expression to recover. Both mechanisms have been demonstrated in animal colitis models.

Can mushrooms prevent intestinal permeability?

In preclinical research, several mushroom polysaccharides have prevented or reversed experimentally induced intestinal permeability. Hericium erinaceus polysaccharides prevented gut barrier disruption in colitis and immunocompromised mouse models and in a primate ulcerative colitis model. King Oyster mushroom fermented with human gut microbiota preserved tight junction integrity against a bile acid challenge in human colonic tissue in a 2025 study. Poria cocos showed barrier-protective effects after antibiotic and DSS colitis injury. The honest limitation: no human clinical trial has tested whether mushroom supplementation prevents intestinal permeability in human patients. All evidence is animal-based or tissue-based.

Sources & References

1. 1RTHM-02104·Kerezoudi, Evangelia N et al. (2025). “Pleurotus eryngii Mushrooms Fermented with Human Fecal Microbiota Protect Intestinal Barrier Integrity: Immune Modulation and Signalling Pathways Counter Deoxycholic Acid-Induced Disruption in Healthy Colonic Tissue..” Nutrients.Study breakdown →PubMed →↩
2. 2RTHM-01776·Ren, Zhengyu et al. (2023). “Hericium erinaceus mycelium-Derived Polysaccharide Alleviates Ulcerative Colitis and Modulates Gut Microbiota in Cynomolgus Monkeys..” Molecular nutrition & food research.Study breakdown →PubMed →↩
3. 3RTHM-01803·Tian, Baoming et al. (2023). “Ameliorating effects of Hericium erinaceus polysaccharides on intestinal barrier injury in immunocompromised mice induced by cyclophosphamide..” Food & function.Study breakdown →PubMed →↩
4. 4RTHM-01825·Xu, Huachong et al. (2023). “Poria cocos Polysaccharide Ameliorated Antibiotic-Associated Diarrhea in Mice via Regulating the Homeostasis of the Gut Microbiota and Intestinal Mucosal Barrier..” International journal of molecular sciences.Study breakdown →PubMed →↩
5. 5RTHM-02011·Wan, Jin et al. (2024). “Poria cocos polysaccharide alleviates dextran sulphate sodium-induced ulcerative colitis in mice by modulating intestinal inflammatory responses and microbial dysbiosis..” International journal of biological macromolecules.Study breakdown →PubMed →↩